Mark Copeland predicts hospitals will soon use formularies to mandate first-line orthopedic implants based on cost and data. Surgeons employed by health systems may be blocked from choosing pricier options like a $4,500 orthofix, even when clinically preferred. Manufacturers need better tools to show how material differences justify costs.
Chapters
anticipate formularies, and it's going to either come from the hospital health system or the insurance plans where they're, they're going to be saying, this is your first-line agent. And there's no better first-line agent than the gold standard and the bone that that patient came into the hospital with based on all the data. But that's not here yet. But I can tell you, if I were selling your product, And we'll, again, we'll be talking about this in 2 weeks. If I were selling your product, I'd be talking to supply chain saying, hey, you guys are always complaining about all this and you don't know what you're spending and is this a ceramic and is this a— because none of them know. I would have you consider having an algorithm like you do with everything else. It would be hard for a surgeon who's employed to say, no, no, no, no, I'm going to use um, orthofixes that sell base for $4,500 versus